CagriSema (Cagrilintide + Semaglutide)

CagriSema is a once-weekly subcutaneous injection combining two distinct hormonal analogs in a single pen device: cagrilintide (2.4 mg), a long-acting amylin receptor agonist, and semaglutide (2.4 mg), a GLP-1 receptor agonist. Developed by Novo Nordisk, CagriSema targets two complementary satiety and metabolic pathways -- amylin and GLP-1 -- to achieve weight loss outcomes that exceed either component administered alone.

Overview

The rationale for CagriSema rests on the complementary biology of amylin and GLP-1, two hormones co-released from the pancreas in response to food intake but acting through distinct receptor systems and brain regions to regulate appetite, gastric emptying, and glucose homeostasis. By targeting both pathways simultaneously, CagriSema produces greater satiety and metabolic effects than either hormone analog alone.

Cagrilintide is an acylated long-acting analog of amylin (islet amyloid polypeptide), a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells. Amylin acts on receptors in the area postrema and nucleus tractus solitarius to reduce appetite, slow gastric emptying, and suppress postprandial glucagon secretion. Semaglutide mimics GLP-1, acting on hypothalamic and brainstem circuits to suppress appetite, stimulate insulin secretion, and slow gastric emptying through a parallel but distinct pathway.

In the REDEFINE 1 trial, CagriSema produced approximately 22-25% body weight loss at 68 weeks in adults with overweight or obesity, compared to ~16% with semaglutide alone and ~8% with cagrilintide alone -- demonstrating true therapeutic synergy rather than simple additive effects.

Mechanism of Action

CagriSema's dual mechanism targets complementary satiety pathways:

• Amylin pathway (cagrilintide): Cagrilintide activates amylin receptors (calcitonin receptor + RAMP1/2/3 complexes) in the area postrema and lateral parabrachial nucleus. This produces satiety signaling distinct from GLP-1, slows gastric emptying, and suppresses postprandial glucagon release. The acylated C18 fatty acid modification enables albumin binding and weekly dosing (Lau et al., 2015)
• GLP-1 pathway (semaglutide): Semaglutide activates GLP-1 receptors in the hypothalamic arcuate nucleus, paraventricular nucleus, and brainstem, reducing appetite through distinct neural circuits. It also stimulates glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying through vagal afferent and direct CNS mechanisms
• Synergistic satiety: Amylin and GLP-1 act on different but interconnected brain regions controlling food intake. Amylin primarily signals through the hindbrain (area postrema/NTS), while GLP-1 engages both hindbrain and hypothalamic (arcuate nucleus) circuits. Combined activation produces greater appetite suppression than either pathway alone
• Complementary glucose control: In type 2 diabetes, the dual mechanism provides superior glycemic control through multiple non-redundant pathways: insulin secretion (GLP-1), glucagon suppression (both), and gastric emptying delay (both)

Reconstitution Calculator

Research

Safety Profile

CagriSema's adverse event profile is dominated by gastrointestinal effects, consistent with both amylin and GLP-1 receptor agonism:

• Gastrointestinal: Nausea (the most common AE, ~25-30%), vomiting, diarrhea, constipation. These effects are generally mild-to-moderate, most common during dose escalation, and diminish over time. The GI AE rate with CagriSema is modestly higher than semaglutide alone.
• Injection site reactions: Mild injection site reactions reported infrequently, consistent with semaglutide monotherapy.
• Hypoglycemia: Low risk when used without insulin or sulfonylureas. Risk increases with concomitant insulin use.
• Thyroid: Semaglutide component carries a boxed warning for thyroid C-cell tumors based on rodent studies. Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
• Pancreatitis: Cases reported at rates similar to semaglutide monotherapy. Monitor for signs/symptoms.
• Discontinuation rates: Treatment discontinuation due to adverse events was slightly higher with CagriSema (~6-8%) versus semaglutide alone (~4-5%) in REDEFINE trials.

Pharmacokinetic Profile

Ongoing & Future Research

• REDEFINE 3: Head-to-head comparison of CagriSema versus tirzepatide 15 mg for weight loss.
• Regulatory submissions for obesity and type 2 diabetes indications in US, EU, and other markets (anticipated 2025-2026).
• Investigation of cardiovascular outcomes (MACE reduction) with CagriSema in dedicated CV outcome trials.
• Long-term durability studies examining weight maintenance beyond 68 weeks.
• Exploration of CagriSema for MASH/NASH, given the liver-related benefits demonstrated by semaglutide monotherapy.